Boris Kovatchev headshot
BK

Boris P. Kovatchev

Professor
Adjunct Professor, School of Engineering and Applied Science
Founding Director, UVA Center for Diabetes Technology.
Unit: School of Medicine
Department: Department of Psychiatry and NB Sciences
Office location and address
560 Ray C. Hunt Dr
Charlottesville, Virginia 22903
Education
BS, Mathematics, Sofia University
MS, Mathematics, Sofia University
PhD, Probability & Statistics, Sofia University
Biography

Dr. Boris P. Kovatchev is Professor at the University of Virginia (UVA) School of Medicine, Adjunct Professor at the School of Engineering and Applied Science, and the founding Director of the UVA Center for Diabetes Technology. He received his Ph.D. in Mathematics from Sofia University “St. Kliment Ohridski,” Bulgaria in 1989. Kovatchev has a 25-year track record in mathematical modeling and computing, with primary focus on diabetes technology since 1996. Currently, he is Principal Investigator of several large projects dedicated to the development and clinical testing of closed-loop control and advisory systems for diabetes, including: (i) the JDRF Artificial Pancreas Project at UVA – a multi-center study that along with UVA involves Stanford University, UC Santa Barbara, the Universities of Padua (Italy) and Montpellier (France), and the Schneider Children’s Medical Center in Israel; (ii) NIH/JDRF Project “Nightlight” focusing on overnight artificial pancreas and run at UVA, Mount Sinai School of Medicine in New York City, the Mayo Clinic in Rochester, MN, and in Padua;  (iii) NIH Diabetes Impact Project DP3 DK 101055 at UVA and Stanford aiming to reduce the risk for hypoglycemia in people who are hypoglycemia unaware; and (iv) NIH RO1 DK 051562 focusing on the control of glucose variability. Kovatchev is also Co-Principal Investigator of a multi-center NIH Diabetes Impact Project (DP3 DK 094331) at UC Santa Barbara, UVA, and the Mayo Clinic and leads industry-sponsored studies.  His projects resulted in in the [only] computer simulator of the human metabolic system accepted by FDA as a substitute to animal trials for the pre-clinical testing of insulin treatments for diabetes, and in the first [worldwide] outpatient trials of portable artificial pancreas. Kovatchev is author of over 160 peer-reviewed publications and is a member of the editorial boards of IEEE Transactions on Biomedical Engineering and the Journal of Diabetes Science and Technology. He holds 38 U.S. and international patents and has numerous patent applications currently pending. In 2008 he received the U.S. Diabetes Technology Leadership Award; in 2011 he was named the UVA’s Edlich-Henderson Inventor of the Year, and in 2013 he was the recipient of JDRF’s Gerold and Kayla Grodsky Award presented for outstanding scientific contributions to diabetes research.


DexCom Master Research Agreement
Source: DexCom, Inc.
August 18, 2020 – August 17, 2025
MD-PSCH Biobehavioral Human-Machine Co-adaptation of the Artificial Pancreas
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
July 01, 2020 – March 31, 2025
Novo Nordisk - UVA Master Research Collaboration Agreement
Source: Novo Nordisk A/S
November 15, 2019 – November 15, 2024
MD-PSCH Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
January 01, 2016 – August 31, 2021
MD-PSCH Closed Loop Control Modalities in Type 1 Diabetes: Efficacy and System Acceptance
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
March 01, 2015 – June 30, 2020
Relative Efficacy of Single-, Bi-, and Tri-Hormonal Closed-Loop Control Systems
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
December 20, 2017 – April 30, 2020
MD-PSYCH Network Control of Diabetes: Aligning Artificial Pancreas Design with Physiology
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
September 30, 2013 – June 30, 2018
MD-PSCH Relative Efficacy of Single, Bi-, and Tri-Hormonal Closed-Loop Closed Systems
Source: Mayo Clinic Rochester
July 21, 2015 – July 31, 2017
MD-PSCH Model-Based Tracking of Hemoglobin A1c with Reference A1c Calibration; Model-Based Tracking of Risk for Hypoglycemia in Diabetes
Source: Sanofi-Aventis Deutschland GmbH
January 27, 2015 – February 04, 2017
MD-PSYCH Network Control of Diabetes: Aligning Artificial Pancreas Design with Physiology
Source: U.S. National Institutes of Health (NIH)
September 30, 2013 – September 30, 2016
MD-PSYCH Ambulatory Artificial Pancreas: Merging Physiology, Behavior and Control Design
Source: University of California, Santa Barbara
September 30, 2011 – June 30, 2016
MD-PSYCH Amylin Research Study Support and Data Sharing Agreement
Source: Amylin Pharmaceuticals, Inc.
June 24, 2011 – June 24, 2016
Systems Approach to Closed Loop Control of Type 1 Diabetes at Home
Source: Juvenile Diabetes Research Foundation Internatl.
September 01, 2011 – December 31, 2015
MD-PSYCH Accuracy Requirements for Non-Adjunct Use of Continuous Glucose Monitoring (CGM)
Source: Becton, Dickinson & Company
September 30, 2013 – September 30, 2015
MODULAR BIO-BEHAVIORAL CLOSED LOOP CONTROL OF TYPE 1 DIABETES
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
September 28, 2009 – February 28, 2015
MD-PSYCH Model-Based Tracking of Changes in Average Glycemia in Diabetes
Source: Sanofi-Aventis Deutschland GmbH
July 26, 2012 – May 31, 2014
In Silico & In Vivo Studies of Glucose Control in the ICU
Source: University of Texas Health Science Center of San A
June 01, 2009 – September 29, 2013
InSpark Technologies, Inc., http://insparktech.com/
TypeZero Technologies, Chief Mathematician http://typezero.com/